TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28941998

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 27322745

Group type: EXPERIMENTAL
Intervention: 2.4% nicotine electronic cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.8% nicotine electronic cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No nicotine electronic cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Failures and reducers (control group)
Number of subjects: 0
Study: 25038542

Group type: EXPERIMENTAL
Intervention: Low anterior resection with ileostomy (LAR with ileostomy)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Low anterior resection without ileostomy (LAR without ileostomy)
Number of subjects: 78
Study: 22112743

Group type: EXPERIMENTAL
Intervention: Coadministration of rosuvastatin (20 mg/day), ezetimibe (10 mg/day), and granulated colestimide (3.62 g/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Rosuvastatin alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coadministration of rosuvastatin, ezetimibe, and colestimide
Number of subjects: 17
Study: 20531018

Group type: EXPERIMENTAL
Intervention: SMOFlipid 20% (study group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional lipid emulsion (Intralipid 20%, control group)
Number of subjects: 60
Study: 18262192

Group type: EXPERIMENTAL
Intervention: 2g LUVs infusion
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 8g LUVs infusion
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined 2g and 8g LUVs infusion
Number of subjects: 75
Study: 15681956

Group type: EXPERIMENTAL
Intervention: Ropivacaine, 0.2% administered at 5 ml/h through the IC catheter for 48 hours
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (NaCl, 0.9%) administered at 5 ml/h through the IC catheter for 48 hours
Number of subjects: 36
Study: 14597107

Group type: EXPERIMENTAL
Intervention: Pentamidine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSF cell counts of 11‐20 cells/microl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal IgM synthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSF end‐titres in LATEX/IgM >/=4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LATEX/T.b. gambiense positive CSF
Number of subjects: 0
Study: 10550734

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg once daily
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 180 mg once daily
Number of subjects: 821

Group type: COMPARATOR
Intervention: Cetirizine 10 mg once daily (active control)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 821
Study: 8810686

Group type: EXPERIMENTAL
Intervention: Combination therapy with cyclosporin (CyA) and methotrexate, mean final dose of 2.97 mg/kg per day CyA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 0
Study: 1921733

Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta-oestradiol (E2) + 50 mg micronized progesterone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta-oestradiol (E2) + 100 mg micronized progesterone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta-oestradiol (E2) + 200 mg micronized progesterone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta-oestradiol (E2) + micronized progesterone (various doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 7048451

Group type: EXPERIMENTAL
Intervention: yohimbine chlorhydrate (4 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: propranolol (40 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 30727991

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational intervention (information flyer as standard of care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 28264176

Group type: EXPERIMENTAL
Intervention: VoiceDiab application
Number of subjects: 54
Study: 25892647

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150mg once daily
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1218
Study: 24315409

Group type: EXPERIMENTAL
Intervention: Educational intervention (two interactive workshops)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (information sent by surface mail)
Number of subjects: 216
Study: 22855064

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18775045

Group type: EXPERIMENTAL
Intervention: Esophageal temperature monitoring (ETM) during pulmonary vein isolation
Number of subjects: 359

Group type: COMPARATOR
Intervention: Non-esophageal temperature monitoring (non-ETM) during pulmonary vein isolation
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Both ETM and non-ETM groups
Number of subjects: 359
Study: 17456173

Group type: EXPERIMENTAL
Intervention: Nursing workload instrument
Number of subjects: 48
Study: 15823766

Group type: EXPERIMENTAL
Intervention: Cefdinir 600 mg once daily for 10 days
Number of subjects: 271

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily for 10 days
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 271

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 271
Study: 12177080

Group type: EXPERIMENTAL
Intervention: Experimental group (evidence based educational outreach visit)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Placebo group (non-structured educational session)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study: 9585747

Group type: EXPERIMENTAL
Intervention: $10 monetary incentive
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: $5 monetary incentive
Number of subjects: 1004

Group type: COMPARATOR
Intervention: No monetary incentive
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Educational intervention (brief motivational education session)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Prevalence of TB infection
Number of subjects: 1004
Study: 7698317

Group type: EXPERIMENTAL
Intervention: Cu(II)(aq.) added to isolated samples of RA SF ultrafiltrates
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cu(II) treated samples of intact SF
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cu(II) ions in inflammatory SF
Number of subjects: 7
Study: 2692973

Group type: EXPERIMENTAL
Intervention: Flupenthixol (0.5 mg tablet in the morning, placebo at night)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sustained-release amitriptyline (25 mg capsule at night, placebo in the morning)
Number of subjects: 51
Study: 856371

Group type: EXPERIMENTAL
Intervention: Intensive individual anti-smoking advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30782000

Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (TH) 40 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) 100 IU
Number of subjects: 105

Group type: COMPARATOR
Intervention: Saline solution (SS) 0.9%
Number of subjects: 105
Study: 29049653

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 2.5 mg
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 5 mg
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 10 mg
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 20 mg
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 40 mg (4-week dose escalation)
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Subcutaneous semaglutide 1.0 mg
Number of subjects: 632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632
Study: 26056177

Group type: EXPERIMENTAL
Intervention: Bortezomib-Dexamethasone (VD)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Bortezomib-Thalidomide-Dexamethasone (VTD)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Bortezomib-Melphalan-Prednisone (VMP)
Number of subjects: 502
Study: 23474578

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ferric sulphate
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Formocresol
Number of subjects: 54
Study: 21147421

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Number of subjects: 31
Study: 18447101

Group type: EXPERIMENTAL
Intervention: Combination treatment of bupropion, nicotine patch, and individual counseling for 8 weeks
Number of subjects: 559
Study: 16528136

Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-80 mg b.i.d.)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Amisulpride (50-100 mg b.i.d.)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 123

Group type: COMPARATOR
Intervention: Amisulpride
Number of subjects: 123
Study: 12972678

Group type: EXPERIMENTAL
Intervention: Stress condition (after giving a videotaped speech)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control condition (after reading children's magazines)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low heart-rate reactivity group
Number of subjects: 25
Study: 11012492

Group type: EXPERIMENTAL
Intervention: Peribulbar block with 10 ml of 0.25% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous morphine 150 microg.kg‐1
Number of subjects: 60
Study: 8934062

Group type: EXPERIMENTAL
Intervention: Vaginal ultrasound evaluation
Number of subjects: 235

Group type: COMPARATOR
Intervention: No ultrasound evaluation (Control)
Number of subjects: 235
Study: 1329742

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g orally b.i.d.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10269519

Group type: EXPERIMENTAL
Intervention: Small group with feedback on individual performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small group without feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual with feedback
Number of subjects: 0
Study: 31761958

Group type: EXPERIMENTAL
Intervention: Topical rapamycin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29641348

Group type: EXPERIMENTAL
Intervention: Translumbar laparoendoscopic single‐site donor nephrectomy (LESS‐DN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 50
Study: 27798035

Group type: EXPERIMENTAL
Intervention: Mediterranean-based dietary intervention supplemented with extra virgin olive oil and mixed nuts until delivery.
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Mediterranean-based dietary intervention
Number of subjects: 1230
Study: 25243546

Group type: EXPERIMENTAL
Intervention: Posterior retroperitoneoscopic adrenalectomy (PRA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lateral transperitoneal laparoscopic adrenalectomy (LTLA)
Number of subjects: 65
Study: 22385499

Group type: EXPERIMENTAL
Intervention: Simulator training sessions with video-based feedback (Feedback group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Driving refresher course without driving-specific feedback (Control group)
Number of subjects: 22
Study: 19377716

Group type: EXPERIMENTAL
Intervention: Oral cancer screening by visual inspection (3 rounds between 1996 and 2004)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral cancer screening by visual inspection
Number of subjects: 13
Study: 17576782

Group type: EXPERIMENTAL
Intervention: Thrice-daily hydrocortisone dosing (mean total daily dose: 8.3 +/- 2.6 mg/m2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Twice-daily hydrocortisone dosing (mean total daily dose: 7.6 +/- 2.1 mg/m2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Morning doses > 4 mg/m2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Evening doses > 2.5 mg/m2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cognitive testing (34 paired tests)
Number of subjects: 20
Study: 15120772

Group type: EXPERIMENTAL
Intervention: Topically applied morphine sulfate 10 mg in Intrasite gel
Number of subjects: 6

Group type: COMPARATOR
Intervention: Subcutaneously administered morphine sulfate 10 mg
Number of subjects: 6
Study: 11460523

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study: 9513329

Group type: EXPERIMENTAL
Intervention: Propofol and small dose of fentanyl (Group P)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Thiopental and sevoflurane (Group S)
Number of subjects: 33
Study: 7800156

Group type: EXPERIMENTAL
Intervention: Glucose drinks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased blood glucose levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 3396472

Group type: EXPERIMENTAL
Intervention: Cefotaxime plus metronidazole
Number of subjects: 175

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 175
Study: 29800584

Group type: EXPERIMENTAL
Intervention: Compound unconditioned stimulus (UCS) - electric shock combined with a scream noise
Number of subjects: 274

Group type: COMPARATOR
Intervention: Demographic factors (race, age, education, gender)
Number of subjects: 274
Study: 28472588

Group type: EXPERIMENTAL
Intervention: Demonstration-based training group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Brochure group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine care-receiving group
Number of subjects: 90
Study: 26258311

Group type: EXPERIMENTAL
Intervention: Cryopreserved packed red blood cells (CPRBCs)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Young liquid packed red blood cells (LPRBCs)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Old liquid packed red blood cells (LPRBCs)
Number of subjects: 256
Study: 24119160

Group type: EXPERIMENTAL
Intervention: Mediopatellar plica (type A, B, or C)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Mediopatellar plica
Number of subjects: 342
Study: 21059991

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 18246678

Group type: EXPERIMENTAL
Intervention: Rehmannia Oral Liquid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiotherapy (Control)
Number of subjects: 60
Study: 15170087

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (IRT) using rhenium-188-filled balloon system
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study: 11219972

Group type: EXPERIMENTAL
Intervention: 5-FU/leucovorin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-FU (bolus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential methotrexate followed by i.v. bolus 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate/5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusional 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leucovorin-modulated 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protracted infusional 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of 5-FU
Number of subjects: 0
Study: 9640152

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1 with glycopyrrolate 200 micrograms
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline placebo only
Number of subjects: 40

Group type: COMPARATOR
Intervention: glycopyrrolate 200 micrograms only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: glycopyrrolate 200 micrograms and remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1
Number of subjects: 40
Study: 8023668

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 2645918

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 120 mg/d given in divided dosage) for twelve weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 120 mg/d given in divided dosage) for four weeks
Number of subjects: 26
Study: 1236737

Group type: EXPERIMENTAL
Intervention: Amino acid mixture simulating casein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tryptic hydrolysate of casein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (fasting subjects)
Number of subjects: 0
Study: 31688091

Group type: EXPERIMENTAL
Intervention: Antisense-oligonucleotide therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RNA interference therapy
Number of subjects: 0
Study: 30316998

Group type: EXPERIMENTAL
Intervention: PeerFIT (group lifestyle intervention enhanced with mobile health technology)
Number of subjects: 144

Group type: COMPARATOR
Intervention: BEAT (one‐on‐one mobile lifestyle coaching with Basic Education in fitness and nutrition supported by a wearable Activity Tracking device)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: PeerFIT
Number of subjects: 144
Study: 28805299

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Apixaban 5 mg twice daily
Number of subjects: 24
Study: 25868579

Group type: EXPERIMENTAL
Intervention: Gemcitabine/Dexamethasone/Cisplatin (GDP)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Cytarabine/Dexamethasone/Cisplatin (DHAP)
Number of subjects: 519
Study: 23020631

Group type: EXPERIMENTAL
Intervention: Professional cleaning of teeth and dentures with individual instruction and re-instruction by a dentist (n = 27)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Professional cleaning of teeth and dentures with individual instruction and help from staff educated in dental hygiene (n = 26)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Professional cleaning of teeth and dentures with individual instruction without further remotivation (n = 26)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No intervention (control group, n = 23)
Number of subjects: 106
Study: 21398375

Group type: EXPERIMENTAL
Intervention: Core dissemination (provision of the 2000 Public Health System Clinical Practice Guideline and a tested smoking cessation program, including program supplies and training)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Core dissemination and access to telephone counseling
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Core dissemination, telephone counseling access and outreach visits to clinics
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study: 18512816

Group type: EXPERIMENTAL
Intervention: Oral bovine type I collagen (500 microg/day)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 16551144

Group type: EXPERIMENTAL
Intervention: Universal cognitive-behavioral approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indicated cognitive-behavioral approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined universal plus indicated cognitive-behavioral approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Universal intervention
Number of subjects: 0
Study: 15070917

Group type: COMPARATOR
Intervention: Ethinylestradiol-drospirenone (OC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Flutamide (62.5 mg/d) plus Metformin (850 mg/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ethinylestradiol-drospirenone (OC) alone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol-drospirenone (OC) plus Flutamide-Metformin
Number of subjects: 54
Study: 11458414

Group type: EXPERIMENTAL
Intervention: PTCR
Number of subjects: 502

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 502
Study: 10137725

Group type: EXPERIMENTAL
Intervention: Intensified control
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional control
Number of subjects: 1441
Study: 2577220

Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clobazam 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1098867

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (Septrin)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 22
Study: 31295757

Group type: EXPERIMENTAL
Intervention: Physician introducing counselor and psychology services (PI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Counselor introducing psychology services alone (CI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions (PI and CI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physician offering psychology services
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perceived helpfulness of psychology services for self
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perceived helpfulness of psychology services for family/caregivers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Younger patients (<40 years) preference
Number of subjects: 100
Study: 27644454

Group type: EXPERIMENTAL
Intervention: Active tDCS combined with virtual reality training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation combined with virtual reality training
Number of subjects: 20
Study: 26087226

Group type: EXPERIMENTAL
Intervention: Web-based alcohol treatment program with intensive asynchronous therapeutic support
Number of subjects: 144
Study: 23525086

Group type: EXPERIMENTAL
Intervention: Reamed nailing for closed fractures
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Reamed nailing for closed fractures (first 35 patients)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Reamed nailing for closed fractures (after 543 patients)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Reamed nailing for open fractures (after 62 patients)
Number of subjects: 1226